DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Kudo M, Finn RS, Qin S. et al.
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Lancet 2018;
391: 1163-1173
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.